Bevacizumab
Composition
Contains Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A).
Indications
Used for treatment of various cancers including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, and cervical cancer.
Side effects
Hypertension, bleeding, proteinuria, impaired wound healing, gastrointestinal perforation, thromboembolic events.
Precautions
Monitor blood pressure, proteinuria, and signs of bleeding or thrombosis; delay surgery due to wound healing risk.
Contraindications
Recent surgery, uncontrolled hypertension, hypersensitivity to bevacizumab.
Dosage and administration
Administered by intravenous infusion; dose and schedule vary by cancer type .
Countries
Available Forms
Injectable solution for intravenous use.